Application of orange essential oil as an antistaphylococcal agent in a dressing model

Arunachalam Muthaiyan, Debabrata Biswas, Philip G Crandall, Brian J Wilkinson and Steven C Ricke*

Abstract

Background: *Staphylococcus aureus* is the pathogen most often and prevalently involved in skin and soft tissue infections. In recent decades outbreaks of methicillin-resistant *S. aureus* (MRSA) have created major problems for skin therapy, and burn and wound care units. Topical antimicrobials are most important component of wound infection therapy. Alternative therapies are being sought for treatment of MRSA and one area of interest is the use of essential oils. With the increasing interest in the use and application of natural products, we screened the potential application of terpeneless cold pressed Valencia orange oil (CPV) for topical therapy against MRSA using an *in vitro* dressing model and skin keratinocyte cell culture model.

Methods: The inhibitory effect of CPV was determined by disc diffusion vapor assay for MRSA and vancomycin intermediate-resistant *S. aureus* (VISA) strains. Antistaphylococcal effect of CPV in an *in vitro* dressing model was tested on *S. aureus* inoculated tryptic soya agar plate. Bactericidal effect of CPV on MRSA and VISA infected keratinocyte cells was examined by enumeration of extra- and intra-cellular bacterial cells at different treatment time points. Cytotoxic effects on human skin cells was tested by adding CPV to the keratinocyte (HEK001) cells grown in serum free KSFM media, and observed by phase-contrast microscope.

Results: CPV vapour effectively inhibited the MRSA and VISA strains in both disc diffusion vapour assay and *in vitro* dressing model. Compared to untreated control addition of 0.1% CPV to MRSA infected keratinocyte decreased the viable MRSA cells by 2 log CFU/mL in 1 h and in VISA strain 3 log CFU/mL reduction was observed in 1 h. After 3 h viable *S. aureus* cells were not detected in the 0.2% CPV treatment. Bactericidal concentration of CPV did not show any cytotoxic effect on the human skin keratinocyte cells *in vitro*.

Conclusions: At lower concentration addition of CPV to keratinocytes infected with MRSA and VISA rapidly killed the bacterial cells without causing any toxic effect to the keratinocytes. Therefore, the results of this study warrant further in vivo study to evaluate the potential of CPV as a topical antistaphylococcal agent.

Keywords: MRSA, VISA, *S. aureus*, Antibiotic resistance, Natural antimicrobials, Orange essential oil

Background

The highly adaptive *S. aureus* is the causative agent of a wide variety of human infections, ranging from superficial skin infections to deep abscesses and more serious life threatening infections [1]. Since the 1990s, methicillin-resistant *S. aureus* (MRSA) has accounted for an increasing proportion of community associated infections in the U.S. [1,2]. MRSA has become a primary cause of skin and soft tissue infections among persons without extensive exposure to healthcare settings. Data obtained from nationally representative ambulatory care surveys in the U.S. show that the infections associated with skin and soft-tissue increased from 8.6 million in 1997 to 14.2 million in 2005 [3]. Skin and soft tissue infections (SSTIs) involve microbial invasions of the primary host defence barriers epidermis and underlying soft tissues [4,5]. Likewise, patients hospitalized with burn wounds are at increased risk of developing microbial colonization and infection caused by *S. aureus*. Previous studies revealed that *S. aureus* is the most frequently isolated bacterial species among the other pathogens from the burn wounds [6,7].

Generally dressings and topical antimicrobial agents are routinely used to prevent skin and burn infections...
and also to keep the wound moist to promote healing [6]. Although, a small number of antibiotics are used as prophylactics to prevent wound infection they are not routinely administered to burn patients due to the high cost and the risk of adverse side effects [8]. Since, the constant use of antibiotics select the bacterial populations including *S. aureus* that are resistant to multiple antibiotics alternative therapies and new medical practices are very much needed [9–11]. One such approach is the search of biologically active pharmacophores from natural resources and traditional medicines [12–16]. Natural products have been investigated and utilized to alleviate disease since early human history. Before the “synthetic era”, 80% of all medicines were obtained from roots, barks, leaves, flowers, seeds and fruits [17].

Numerous studies have explored the promising novel antimicrobial candidates from plant derived essential oils (EOs). These EOs are particularly interesting since some oils have been used by native groups for curative purposes in the past [18,19]. Many plants EOs have demonstrated for antimicrobial activity against variety of bacterial pathogens [20,21]. One such a prominent example is tea tree oil obtained from the Australian tree *Melaleuca alternifolia*. Tea tree oil has been shown to be active against a wide range of microorganisms including *S. aureus* [20,22]. In previous studies the antimicrobial activities of EOs have also been investigated and their actions against various pathogens, including clinical MRSA isolates, have been demonstrated [23–30].

Fisher et al. reported the effectiveness of citrus EOs and vapours of lemon and the citrus EO components citral, limonene, and linalool against a number of common foodborne pathogens *Listeria monocytogenes, S. aureus, Bacillus cereus, E. coli O157,* and *Campylobacter jejuni* both in vitro and on food models [31]. In our laboratory we have demonstrated the inhibition of *Salmonella* [32], *Listeria* [33,34], *Escherichia coli* O157: H7 [35], *Campylobacter* [36], and methicillin resistant *S. aureus* [37] by citrus derived cold pressed Valencia orange oil, terpeneless Valencia orange oil, cold pressed orange terpenes, high purity orange terpenes, d-limonene, and terpenes from orange essence. In our previous study the inhibitory and cell wall lytic effect of 0.1% and 0.2% cold pressed terpeneless Valencia orange oil (CPV) against MRSA and VISA was demonstrated by disc diffusion and agar dilution methods and confirmed by genomic transcriptional profiling and electron microscopy [37]. With the increasing interest in the use and application of natural antimicrobial agents for the therapy in the present study we evaluated the potential of CPV for topical therapy against MRSA by determining the antistaphylococcal effect of CPV in dressing model and *S. aureus* infected keratinocyte cell culture study.

**Methods**

**Bacterial strains**

Methicillin-susceptible *S. aureus* strain SH1000 [38], methicillin-resistant strains COL [39], 13136 p m^−1 [40], and N315 [41], and vancomycin intermediate-resistant strains 13136 p m^−1 V20 [42], and Mu50 [41] were used in this study. Depending on the experimental condition described in the following sections bacterial strains were grown in either tryptic soya broth (TSB) or tryptic soya agar (TSA) media (Difco Laboratories, Inc. Detroit, MI) and incubated at 37°C for 18 h.

**Orange essential oil**

Commercially available terpeneless cold pressed Valencia orange oil was obtained from Firmenich Citrus Center, Safety Harbor, FL, USA. CPV is derived from mechanical extraction of the orange oil which is further concentrated under vacuum [43]. The major components of CPV are Linalool 20.2%, Decanal 18%, Geranial 9.1%, α-Terpineol 5.8%, Valencene 5.2%, Neral 5%, Dodecanal 4.1%, Citronellal 3.9%, and Limonene 0.3% [36]. The most predominant compounds are the alcohol linalool (20.2%) followed by decanal (18%), and geranial (9.1%), the amount of limonene is much lower at 0.3% [36].

**Disc diffusion vapor assay for screening the inhibitory effect of CPV**

Disc diffusion vapor assay was carried out by the method described by Goñi et al. [44] and Edwards-Jones et al. [45]. Overnight cultures of the *S. aureus* (7 log CFU/mL) were streaked on sterile TSA (Difco Laboratories, Inc.) using a cotton swab dipped into the culture. The swab was used to streak the agar plate to produce a lawn of growth by streaking the plate in 3 different directions. Ten μL of 100% CPV was aseptically pipetted onto sterile 6-mm paper discs (Becton Dickson, Franklin Lakes, NJ) and subsequently the CPV impregnated paper discs were aseptically placed in the centre of the lid of the Petri dish. Control plates were prepared by adding 10 μL of sterile water to the filter discs. The Petri dishes were subsequently sealed using parafilm and incubated at 37°C in an inverted position. The diameters of zones of inhibitions were measured in mm after 24 h of incubation. The assays were carried out on three different occasions in duplicate.

**In vitro dressing model study**

*In vitro* dressing model was designed by a modification of the method described by Edwards-Jones et al. [45]. Briefly, 10 μL aliquot of CPV (100%) was spotted in four different areas on the sterile 10.2 x 10.2 cm, 12 ply cotton gauze dressing pad (Duka Corp. Happauge, NY) (Figure 1a). For control plates 10 μL of sterile deionized water was spotted in the gauze dressing pad. TSA plates were seeded with a suspension of 7 log CFU/mL of...
MRSA strains COL, Mu50 or VISA strain 13136 p-m+ V20 and covered with single layer of sterile bandage (QMD Medical, Québec, Canada) without touching the inoculated agar surface. As shown in Figure 1a CPV spotted gauze dressing pad was placed on the bandage by CPV spots facing towards the inoculated agar surface and wrapped with bandage to hold the gauze dressing pad on the Petri plate (Figure 1b). The dressing model Petri plates were subsequently incubated at 37°C for 24 h and the treated plates were compared with untreated control to identify the visible inhibition zones. This study was carried out on three different occasions in duplicate.

Keratinocyte cell culture

_Homo sapiens_ skin keratinocyte (HEK001) ATCC CRL-2404™ cells were grown in keratinocyte serum free media (K-SFM) with two additives, bovine pituitary extracts (BPE) and human recombinant epidermal growth factor (EGF) (Invitrogen, Carlsbad, CA). Cells were grown routinely in a 75 cm² flask at 37°C in a 5% CO₂-humidified incubator. Ninety percent confluent cultures were trypsinized, and new cultures were prepared by seeding with 10⁵ cells/ml in 75 cm² flasks. For cytotoxicity and infection assays, BD Falcon™ 24-well tissue culture plates (BD, Franklin Lakes, NJ) were seeded with 10⁵ cells/ml/well and incubated at 37°C in a humidified 5% CO₂ incubator for 18 to 20 h to obtain a semi-confluent monolayer. Prior to assays, the monolayers were washed and incubated with K-SFM medium without antibiotic.

**Figure 1 Dressing model using an agar plate.** (a), arrows indicate the CPV spots on gauze dressing pad; (b), complete setup of dressing model with gauze dressing pad wrapped with bandage. Untreated control plates of _S. aureus_ strains (c), COL; (d), Mu50; and (e), 13136 p-m+ V20. Inhibition of _S. aureus_ (f), COL; (g), Mu50; and (h), 13136 p-m+ V20 caused by CPV.

**Cytotoxicity assay**

The MIC of CPV for the 6 _S. aureus_ strains used in this study was previously determined as 0.18% for the strains 13136 p-m+ and 13136 p-m+V20 and 0.2% for strains COL, Mu50, and N315 [37]. Based on our previous results, 0.1% and 0.2% of CPV was prepared using dimethyl sulfoxide (DMSO) as a dispersing agent and added to the HEK001 cell monolayers and incubated for 24 h. After incubation, the cell monolayer was observed under phase-contrast microscope (Olympus, Japan). One set of HEK001 cell monolayer without any treatment and another set with equal volume of DMSO used in the CPV treatment were used as controls. To compare a typical cytotoxicity one set of HEK001 cell monolayer was treated with a known skin irritant SDS (25 μg/mL) [46].

**S. aureus infection assay**

Adherence and invasion assays were performed using a modified procedure derived from Harvey et al. [47]. Briefly, one loopful of overnight grown bacterial cells were collected from TSA plates and suspended in K-SFM media with additives. Aliquots (100 μl) of the bacterial suspension, containing approximately 7 log CFU/mL [multiplicity of infection (MOI) 1:100], were inoculated in duplicate in a 24-well tissue culture plate containing semi-confluent HEK001 cell monolayers. The CFUs of bacteria were determined simultaneously by serial dilution plate count on TSA plates. Infected monolayers were incubated for 2 h at 37°C under a 5% CO₂ humidified atmosphere to allow the bacterial cells to adhere and infect the HEK001 cells. Infected HEK001 monolayers were washed five times
with K-SFM medium and re-incubated for 3 h in fresh media containing 0.1 or 0.2% CPV. For controls, infected HEK001 monolayers were re-incubated with fresh K-SFM medium alone or K-SFM medium with equal volume of DMSO used in CPV treatment. After 1, 2, and 3 h of incubation both controls and CPV treated HEK001 cells were lysed with 0.1% Triton X (Sigma, St. Louis, MO) in PBS for 15 min to detach the bacterial cells and subsequently the lysate containing bacterial cells were diluted and viable intra- and extra-cellular bacterial numbers were determined by counting the CFU on TSA plate. Results are expressed as the average number of bacterial CFU from three assays.

Results and discussion
Effect of CPV vapour on S. aureus
In an effort to explore the potential use of orange EO against antibiotic resistant S. aureus, in our earlier study inhibitory effects and mode of action of CPV against methicillin-susceptible strain SH1000, MRSA strains COL, 13136 p·m⁻¹, and N315, and VISA strains 13136 p·m⁻¹V₂₀, and Mu50 were studied [37]. Compared to other tested EOs CPV effectively inhibited all the tested S. aureus strains [37]. Therefore, in the present study the effect of CPV vapour on S. aureus was examined on both agar plates and an in vitro dressing model to evaluate the potential of CPV for topical therapy. Generally to study the antimicrobial effect of vapour, EO impregnated paper disc is placed on the lid of Petri dish and subsequently the growth inhibition zone is measured and used to indicate the antimicrobial effect of EO [19,21].

In our disc diffusion CPV vapour study, growth of all the six S. aureus strains were inhibited at different levels (Table 1). The maximum diameter of inhibition zone 78.8 ± 1.8 mm was observed in VISA strain 13136 p·m⁻¹V₂₀ followed by the MRSA strains 13136 p·m⁻¹, COL, N315, and Mu50. The lower diameter of inhibition zone 17.8 ± 1.4 mm was observed in an antibiotic susceptible strain SH1000. Similar to our observation, strain specific variation in the growth inhibition in S. aureus was previously observed by Edwards-Jones et al. [45]. In their study, the most effective combination of geranium and commercial grapefruit extract Citricidal™ vapour against MRSA did not affect the growth of antibiotic susceptible S. aureus strain NCTC 6571 [45]. It has been previously noted that the degree of inhibition of bacterial growth by EOs considerably varies due to the complexity of EOs and characteristics of bacterial strains [48]. Related to results observed in our study Gaunt et al. [49] demonstrated the antistaphylococcal effect of evaporated volatile compounds from orange oil. In their study, agar plates inoculated with S. aureus strain 8532 were exposed in a large air-tight chamber to candle flames combined with the volatile bactericidal compounds β-pinene and orange oil and results showed that compared to plain candle addition of volatile oils significantly reduced the number of S. aureus colonies. Goñi et al. [44] also reported the susceptibility of various strains of Gram-negative and -positive microorganisms including S. aureus to vapour phase cinnamon, clove and a mixture of cinnamon and clove EOs. In their study they found that vapour phase of cinnamon, clove or mixture of cinnamon and clove EOs showed better inhibition of S. aureus growth than the direct contact disc diffusion method [44].

Antistaphylococcal effect of CPV vapor in dressing model
Our disc diffusion vapor assay proved that the vapor phase of the volatile components in the CPV serves as possible source of antimicrobial agents. Therefore, we considered assessment of the anti-staphylococcal effect of CPV vapor in an in vitro dressing model to evaluate the potential topical application of CPV. In this experiment the inhibitory effect of CPV was qualitatively evaluated by the presence or absence of inhibition zone by comparing the test and control dressing models (Figure 1c-h). As we observed in the disc diffusion vapor assay a similar inhibitory effect was observed in the dressing model as well. Growth of MRSA strains COL and Mu50 and VISA strain 13136 p·m⁻¹V₂₀ was inhibited by the vapor released from the CPV spotted gauze dressing pad and exhibited a clear inhibition zones on agar plates (Figure 1f-h). Our present study has demonstrated the potential of the CPV as an anti-MRSA agent in the vapor phase in both the disc diffusion assay and the in vitro dressing model. Effectiveness of the vapor phase EOs against microbial growth was shown to be better than the direct contact of EOs with the inoculated culture has already been reported in other studies [44,50]. In an in vitro dressing model study Edwards-Jones et al. [45] demonstrated the inhibitory effect of combination of geranium and commercial grapefruit extract Citricidal™ vapor against MRSA. Results of their study concluded that EOs can be applied as a natural anti-MRSA agent on the outer layer of the dressing without disturbing the normal wound healing process.

| S. aureus strain | Inhibition Zone (mm) ± SD |
|------------------|--------------------------|
| SH1000           | 17.8 ± 1.4               |
| COL              | 64.0 ± 2.2               |
| 13136 p·m⁻¹      | 70.2 ± 1.4               |
| 13136 p·m⁻¹V₂₀   | 78.8 ± 1.8               |
| N315             | 62.6 ± 2.5               |
| Mu50             | 21.0 ± 2.6               |

* Inhibition zones are average values of three independent trials ± standard deviation of the mean (SD, n=6).
Non-cytotoxic effect of CPV on HEK001 keratinocyte cells

Dermal exposure to either synthetic or natural chemical substances can lead to a wide variety of skin reactions. Therefore, it is important to evaluate the new topical therapy agents that can potentially affect the skin cells [51]. Skin is the first-line defense against invading pathogens [52], and is composed of three layers, whereas the outermost epidermis is a squamous epithelium that mainly consists of keratinocytes [53]. Therefore, in this study we used keratinocyte cells as an in vitro model to assess the effect of CPV. Since there are general concerns about the toxicity and adverse effects of the plant derived natural products on the host first we evaluated the toxic effect of CPV on human keratinocyte cell monolayer. In our previous study we have shown that the MIC of CPV for the S. aureus strains used in the present study as 0.18% for the strains 13136 p m+ and 13136 p m+V20 and 0.2% for strains COL, Mu50, and N315 [37]. Therefore, to examine whether CPV has toxic effect on keratinocyte cells, 0.1% (½ x MIC) and 0.2% (1x MIC ) of CPV was added to the HEK001 keratinocyte cell monolayer and subsequently at regular intervals the cell monolayers were examined under phase-contrast microscope for any morphological changes caused by the toxic effect of CPV. Figure 2a is a representative picture of normal keratinocyte cells and DMSO treated cells did not show any toxic effect and looks similar to normal keratinocyte cells (Figure 2b). Figure 2c represents the cytotoxic effect caused by a known skin irritant SDS on cell monolayer. Compared to controls (Figure 2a-c), CPV (0.1% and 0.2%) treated keratinocyte monolayer cells did not exhibit any toxic response even after 24 h of incubation (Figure 2d,e). Result of this observation indicated that the concentration (0.1 and 0.2%) of CPV that has previously shown to be bactericidal for MRSA and VISA cells did not produce any adverse effect on human epidermal keratinocyte cells [37]. Host tolerance is one of the issues that must be considered when evaluating natural antibacterial agents [54]. Many currently available antifungal and antibacterial agent possess undesirable toxicity [16,54]. However, interestingly in our in vitro study the CPV treatment on keratinocyte cells did not exhibit any toxic effect mediated cell death in keratinocyte cells. It indicates the potential suitability of CPV for the topical antimicrobial treatment for dermal S. aureus infections.

Anti-staphylococcal effect of CPV in S. aureus infected keratinocyte cells

Enumeration of total number S. aureus cells infected in HEK001 keratinocyte monolayer indicated that addition of CPV (0.1% or 0.2%) into the infected cells reduced the adhesion of MRSA strain COL and VISA strain 13136p m+V20 to the keratinocyte cells. Infected HEK001 monolayers treated with fresh K-SFM medium alone or
Table 2 Effect of CPV treatment on the total number of S. aureus infected with skin keratinocyte (HEK001) cell monolayer

| S. aureus Strain | Initial Inoculum *(Log CFU/mL)* | Incubation Time (h) | Control *(Log CFU/mL)* | CPV Treatment *(Log CFU/mL)* |
|------------------|---------------------------------|--------------------|-----------------------|-----------------------------|
| COL              | 7.48 ± 0.16                     | 1                  | 5.53 ± 0.45           | 2.84 ± 0.20                 |
|                  |                                 | 2                  | 5.79 ± 0.07           | 2.06 ± 0.38                 |
|                  |                                 | 3                  | 6.30 ± 0.07           | 1.98 ± 0.45                 |
| 13136 p·m⁻¹ V20  | 7.34 ± 0.11                     | 1                  | 5.04 ± 0.13           | 3.47 ± 0.20                 |
|                  |                                 | 2                  | 5.58 ± 0.06           | 2.83 ± 0.15                 |
|                  |                                 | 3                  | 5.88 ± 0.07           | 2.29 ± 0.62                 |

*Inhibition zones are average values of three independent trials ± standard deviation of the mean (SD, n=6). ND – Not detectable.

K-SFM medium mixed with equal volume of DMSO used in CPV treatment were used as controls in this experiment. We did not observe any difference between these two controls (data not shown). Compared to the control, CPV treated keratinocyte exhibited gradual decreases in total numbers of attached S. aureus cells within 3 h of treatment. After 3 h of incubation with 0.2% CPV number of viable COL and 13136 p·m⁻¹ V20 cells became undetectable (Table 2). There are also several clinical studies [55,56] and case reports [57,58] reporting the successful use of EOs in treating MRSA nasal carriage or MRSA infections. Dryden et al. [55] and Caelli et al. [59] reported that a topical tea tree oil treatment was as effective as standard therapy for reducing MRSA nasal colonization. Sherry et al. demonstrated the successful use of the commercial phytochemical mixture Polytoxins™ containing the extracts from Lemongrass, Eucalyptus, Melaleuca, Clove, Thyme as well as B.H.T. (Butylated Hydroxy Toluene), Triclosan (0.3%) and 95 undematured ethano (69.7%) to treat an intractable MRSA infection of the tibia in an adult patient [58]. Previous case studies have also demonstrated the topical use of Eucalyptus oil extracted from the Eucalyptus globulus leaf together with bioethanol for MRSA wound infection. This case study has reported that without administering any antibiotic application of 0.5 g of the oil per day to the wound for three weeks improved wound healing with clearing the MRSA to an undetectable level [60]. Recently, Palaniappan and Holley showed that natural antimicrobials carvacrol, thymol, and cinnamaldehyde were able to substantially decrease the MIC of antibiotics in a diverse group of bacteria containing genetic elements responsible for drug resistance [61]. They have demonstrated the synergistic effect of carvacrol, thymol, and cinnamaldehyde in the reduced MICs of ampicillin, penicillin and bacitracin against penicillin-resistant S. aureus [61]. Thus, we speculate it is possible to use the CPV either single topical agent or synergistically with other antibiotics to control the S. aureus skin infections.

Conclusions

MRSA is common in the U.S. and it accounts for more than half of all soft-tissue and skin infections [2]. Surveillance reports indicate that in the U.S. annual MRSA prevalence continuously increased over the 10-year period from 32.7% in 1998 to 53.8% in 2007 and during the 1999–2006 the percentage of S. aureus infections resistant to methicillin increased greater than 90% in outpatients admitted to U.S. hospitals. Also, MRSA-related hospitalization rate per 1,000 discharges doubled in 2007 [62,63]. Despite major advances in wound and burn management in the new millennium, infection still remains an important factor in wound healing [6]. Novel classes are clearly needed for MRSA, because current drug classes exhibit emerging resistance. We have initiated this study as a first step towards the investigation of potential antistaphylococcal effect of CPV and its usage for skin infection. In this study, we have demonstrated the antistaphylococcal effect of CPV in an *in vitro* dressing model and *S. aureus* infected keratinocyte cell culture study. Overall in the present study our findings suggest that further *in vivo* studies of CPV are warranted since the CPV showed the inhibition and bactericidal effect on MRSA and VISA in the *in vitro* models. While, we provide interesting and valuable basic data for CPV we suggest prior to continuing on for further studies to test the clinical safety and efficacy of the CPV to use as topical anti-MRSA agent comparison of the inhibitory effect of CPV with antibiotics currently used to treat MRSA skin infection would provide additional valid information for the future therapeutic applications.

In our earlier study we have reported the bacteriolytic effect and mechanism of action of CPV in antibiotic resistant *S. aureus* [37]. The next step in this CPV series study focuses the comparison of the inhibitory effect of CPV with standard antibiotic disc assay together with a quality control strains to develop a standard evaluation method to test the inhibitory effect of CPV on more *S. aureus* strains and other pathogens.
Abbreviations
CPV: Terpenes cold-pressed valencia orange oil; EO: Essential oil; MRSA: Methicillin-resistant Staphylococcus aureus; VISA: Vancomycin intermediate-resistant Staphylococcus aureus.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
AM designed and performed the experiments, interpreted the results and drafted the manuscript. AM and DB designed and performed the cell culture experiment and data analysis. PGC, SCR, and BJW participated in the design of the study. SCR critically read the manuscript and participated in revision of the manuscript. All authors have read and approved the final manuscript.

Author details
1 Center for Food Safety and Department of Food Science, University of Arkansas, Fayetteville, AR 72701, USA. 2 Current address: Department of Animal and Avian Sciences, University of Maryland, College Park, MD 20742, USA. 3 Microbiology Group, Department of Biological Sciences, Illinois State University, Normal, IL 61790, USA.

Received: 5 November 2011 Accepted: 8 August 2012

Published: 16 August 2012

References
1. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu Rev Microbiol 2010, 64:1143–162.
2. Chen AE, Goldstein M, Carroll K, Song X, Peru TM, Siberry GK. Evolving epidemiology of pediatric Staphylococcus aureus cutaneous infections in a Baltimore hospital. Pediatr Emerg Care 2006, 22(10):717.
3. Hersch AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008, 168(14):1585–1591.
4. Kish TD, Chang MH, Fung HB. Treatment of skin and soft tissue infections in the elderly: A review. Am J Geri Pharmacother 2010, 8(6):485–513.
5. Koerner R, Johnson AP. Changes in the classification and management of skin and soft tissue infections. J Antimicrob Chemother 2011, 66(11):232–234.
6. Edwards-Jones V, Greenwood JM. What's new in burm microbiology? James Laing Memorial Prize Essay 2000. Burns 2003, 29:115–24.
7. Guggenheim M, Zbinden R, Handschin AE, Gohritz A, Altintas MA, Giovanoli P. Changes in bacterial isolates from burn wounds and their antibiotics: A 20-year study (1986–2005). Burns 2009, 35(4):533–560.
8. Edwards-Jones V, Dawson MM, Childs C. A survey into toxic shock syndrome (TSS) in UK burns units. Burns 2000, 26(4):323–333.
9. Novick RP. MEDICINE: Combating Impervious Bugs. Science 2008, 319(5865):910–911.
10. Pirri G, Giuliani A, Niccolito SF, Pizzuto L, Rinaldi AC. Lipopeptides as anti-infectives: a practical perspective. Centr Eur J Biol 2009, 4(3):258–273.
11. Stein RA. Antibiotic resistance: A global, interdisciplinary concern. The Am Biol Teacher 2011, 73(6):314–321.
12. Saxena S, Kumar D. Tailoring biodiversity for the development of new therapeutics. Nat Prod Rep 2002, 1:18–25.
13. Singh SB, Barrett JE. Empirical antibacterial drug discovery—Foundation in natural products. Biochem Pharmacol 2006, 71(7):1006–1015.
14. Butler MS, Buss AD. Natural products — The future scaffolds for novel antibiotics? Biochem Pharmacol 2006, 71(7):919–926.
15. Patwardhan B, Meshalkar RA. Traditional medicine-inspired approaches to drug discovery: can Ayurveda show the way forward? Drug Discov Today 2009, 14(15–16):804–811.
16. Saleem M, Nazir M, Ali MS, Hussain H, Lee YS, Riaz N, Jabbar A. Antimicrobial natural products: an update on future antibiotic drug candidates. Nat Prod Rep 2010, 27(7):233–254.
17. McChesney JD, Venkataraman SK, Henri JT. Plant natural products: Back to the future or into extinction? Phytochemistry 2007, 68(1):2015–2022.
18. Saravolatz LD, Markowitz N, Arking L, Pohlol D, Fisher E. Methicillin-resistant Staphylococcus Aureus. Ann Intern Med 1982, 96(1):11–16.
19. Burt S. Essential oils: their antibacterial properties and potential applications in foods; a review. Inter J Food Microbiol 2004, 94:223–253.
20. Halcón L, Milkus K. Staphylococcus aureus and wounds: A review of tea tree oil as a promising antimicrobial. Am J Infect 2004, 32(7):402–408.
21. Fisher K, Phillips CA. Potential antimicrobial uses of essential oils in food: is citrus the answer? Trends Food Sci Technol 2008, 19(3):156–164.
22. Hammer KA, Carson CF, Riley TV, Nielsen JB. A review of the toxicity of Melaleuca alternifolia (tea tree) oil. Food Chem Toxicol 2006, 44(3):616–625.
23. Cox S, Gustafson J, Mann C, Markham J, Liew Y, Hartland R, Bell H. Warmington J, Wyllie S. Tea tree oil causes K+ leakage and inhibits respiration in Escherichia coli. Lett Appl Microbiol 1998, 26:355–358.
24. Elsom GKF, Hide D. Susceptibility of methicillin-resistant Staphylococcus aureus to tea tree oil and muromycin. J Antimicrob Chemother 1999, 43(3):427–428.
25. Hammer KA, Carson CF, Riley TV. Antimicrobial activity of essential oils and other plant extracts. J Appl Microbiol 1990, 68(5):693–990.
26. May J, Chan CH, King A, Williams L, French GL. Time-kill studies of tea tree oils on clinical isolates. J Antimicrob Chemother 2000, 45(5):639–643.
27. Takara K, Kimizuka R, Takahashi N, Honma K, Okuda K, Kato T. A comparison of the antibacterial efficacies of essential oils against oral pathogens. Oral Microbiol Immunol 2002, 19:51–4.
28. Brady A, Loughlin R, Gilpin D, Kearney P, Tunney M. In vitro activity of tea-tree oil against clinical skin isolates of meticillin-resistant and -sensitive Staphylococcus aureus and coagulase-negative staphylococci growing planktonically and as biofilms. J Med Microbiol 2006, 55(10):1375–1380.
29. Prabuseenivasan S, Jayakumar M, Ignacimuthu S. In vitro antibacterial activity of some plant essential oils. BMC Complement Altern Med 2006, 6(1):39.
30. Chao S, Young G, Oberg C, Nakaoka K. Traditional medicine-inspired approaches to evincing medicinal plants and other plant extracts. J Med Microbiol 2007, 56(3):264–267.
31. Friedly EC, Crandall PG, Ricke SC, Romain M, O’Byran C, Chalvi VA. In vitro antilisterial effects of citrus oil fractions in combination with organic acids. J Food Sci 2009, 74(2):M67–M72.
32. Shannon EM, Milliro SR, Johnson MG, Ricke SC. Fitness of cost-pressed teapenesva in Valencia and its primary components on inhibition of Listeria species by direct contact and exposure to_Vos. J Food Sci 2011, 76(7):M500–M503.
33. Nannapaneni R, Muthayyan A, Crandall PG, Johnson MG, O’Byran CA, Chalvi VA, Callaway TR, Callaway JM, Arthington JD, Nisbet DJ. Antimicrobial activity of commercial citrus-based natural extracts against Escherichia coli O157:H7 isolates and mutant strains. Foodborne Pathog Dis 2008, 5(5):695–699.
34. Nannapaneni R, Chalvi VA, Crandall PG, Ricke SC, Johnson MG, O’Byran CA. Campylobacter and Arcobacter species sensitivity to commercial orange oil fractions. Int J Food Microbiol 2009, 129(1):43–49.
35. Muthayyan A, Martin EM, Nateran S, Crandall PG, Wilkinson BJ, Ricke SC. Antimicrobial effect and mode of action of terpenes cold-pressed Valencia orange essential oil on meticillin-resistant Staphylococcus aureus. J Appl Microbiol 2012, 112(5):1000–33.
36. Honsburgh MJ, Ash JL, White II, Shaw L, Lithgow JK, Foster SJ. sigmA modulates virulence determinant expression and stress resistance: characterization of a functional rsaB strain derived from Staphylococcus aureus 8325–4. J Bacteriol 2002, 184(19):5657–5667.
37. Sabath LD, Wallace SJ, Byers K, Toftegaard I. Resistance of Staphylococcus aureus to penicillins and cephalosporins: reversal of resistance with some chelating agents. Ann N Y Acad Sci 1974, 236:435–43.
38. Brown DF, Reynolds PE. Intrinsic resistance to beta-lactam antibiotics in Staphylococcus aureus. FEBS Lett 1980, 122(2):275–278.
39. Kuromi M, Ohta T, Kimizuka K, Hama T, Kato T. In vitro antimicrobial activity of Vitis vinifera L. and other plant extracts. J Med Microbiol 2007, 56(10):1375–1380.
40. Pfettz RF, Singh VK, Schmidt JL, Batten MA, Baranyk CS, Nadakavukaren MJ, Jayaswal RK, Wilkinson BJ. Characterization of phase-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds. Antimicrob Agents Chemother 2000, 44(2):294–303.
43. Braddock RJ: Handbook of citrus by-products and processing technology. New York: Willey; 1999.
44. Golp P, López P, Sánchez C, Gómez-Lus R, Becerril R, Nerín C: Antimicrobial activity in the vapour phase of a combination of cinnamon and clove essential oils. Food Chem 2009, 116(4):982–989.
45. Edwards-Jones V, Buck R, Shawcross SG, Dawson MA, Dunn K: The effect of essential oils on methicillin-resistant Staphylococcus aureus using a dressing model. Burns 2004, 30(8):772–777.
46. Chung NM, Marshall CM, Leyden JJ, Lavker RM, Jensen PJ, Marsh BC: Sodium dodecyl sulfate induces plasminogen activator inhibitor type 2 expression in epidermal keratinocytes in vivo and in vitro. J Invest Dermatol 2001, 117(3):647–653.
47. Harvey HA, Jennings MP, Campbell CA, Williams R, Apiella MA: Receptor-mediated endocytosis of Neisseria gonorrhoeae into primary human urethral epithelial cells: the role of the asialoglycoprotein receptor. Mol Microbiol 2001, 42(3):659–672.
48. Dorman HJD, Deans SG: Antimicrobial agents from plants: antibacterial activity of plant volatile oils. J Appl Microbiol 2000, 88(2):308–316.
49. Gaunt LF, Higgins SC, Hughes IF: Interaction of air ions and bactericidal vapours to control micro-organisms. J Appl Microbiol 2005, 99(6):1324–1329.
50. Lopez P, Sanchez C, Batlle R, Nerín C: Solid-and vapor-phase antimicrobial activities of six essential oils: susceptibility of selected foodborne bacterial and fungal strains. J Agric Food Chem 2005, 53(17):6939–6946.
51. Van de Sandt J, Roguet R, Cohen C, Esdaile D, Ponec M, Corsini E, Barker C, Fusenig N, Liebsch M, Benford D: The use of human keratinocytes and human skin models for predicting skin irritation. The Report and Recommendations of ECVAM Workshop. ATLA 1999, 27:273–744.
52. Gallo RL, Nakatsui T: Microbial symbiosis with the innate immune defense system of the skin. J Invest Dermatol 2011, 131(October):1974–1980.
53. Weiss T, Baskett DA, Schöder KR: In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicol In Vitro 2004, 18(3):231–243.
54. Woolf AD: Herbal remedies and children: Do they work? Are they harmful? Pediatrics 2003, 112(1):240–246.
55. Dryden MS, Dailly S, Crouch M: A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 2004, 56(4):283–286.
56. Sherry E, Warnke PH: Successful use of an inhalational phytochemical to treat pulmonary tuberculosis: A case report. Phytomedicine 2004, 11(2–3):95–97.
57. Caelli M, Porteous J, Carson CF, Heller R, Riley TV: Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect 2000, 46(3):236–237.
58. Sherry E, Boeck H, Warnke P: Percutaneous treatment of chronic MRSA osteomyelitis with a novel plant-derived antiseptic. BMC Surgery 2001, 1(1):1.
59. Caelli M, Porteous J, Carson CF, Heller R, Riley TV: Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. Int J Aromatherapy 2001, 11(2):57–69.
60. Sherry E, Boeck H, Warnke PH: Topical application of a new formulation of eucalyptus oil phytochemical clears methicillin-resistant Staphylococcus aureus infection. Am J Infect Control 2001, 29(5):346–346.
61. Palaniappan K, Holley RA: Use of natural antimicrobials to increase antibiotic susceptibility of drug resistant bacteria. Int J Food Microbiol 2010, 140(2–3):164–168.
62. Klein E, Smith DL, Laxminarayan R: Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999–2006. Emerg Infect Dis 2009, 15(12):21925–1930.
63. Mera RM, Suaya JA, Amrine-Madsen H, Hoyega CS, Miller LA, Lu EP, Sahm DF, O’Hara P, Acosta CJ: Increasing role of Staphylococcus aureus and community-acquired methicillin-resistant Staphylococcus aureus infections in the United States: A 10-year trend of replacement and expansion. Microb Drug Resist 2011, 17(2):321–328.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Cite this article as: Muthaiyan et al.: Application of orange essential oil as an antistaphylococcal agent in a dressing model. BMC Complementary and Alternative Medicine 2012 12:125